Lepu Biopharma Co. Ltd. Class H 2157
HKEX · Hong Kong SAR China · Health Technology
HKD 4.04-0.20 (-4.60%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
A late-stage gastric-cancer study met its overall-survival goal, supporting AstraZeneca's multibillion-dollar peak-sales estimate.
Lepu Biopharma (SEHK:2157) stock has shown mixed recent performance, with a gain over the past month but a decline over the past 3 months and the past year, prompting closer investor attention. See our latest analysis for Lepu Biopharma. The recent 7 day share price return of 10.54% contrasts with a 90 day share price decline of 27.85% and a 1 year total shareholder return decline of 17.62%, suggesting momentum has picked up in the short term after a weaker period. If you are comparing Lepu...
On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market launch of MEIYOUHENG®(Becotatug Vedotin injection) , the world's first EGFR-targeting antibody-drug conjugate (ADC). The launch also represents the first ADC fully manufactured by a CDMO to reach the market in China, underscoring a new level of maturity for the region's biopharmaceutical ecosystem.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.